It makes absolutely no sense for an effective cancer treatment to vanish from the market, but it may happen. Despite saving many lives, Zevalin, a radio-immunotherapy drug approved 14 years ago by the Food and Drug Administration, may not be available much longer for patients with non-Hodgkin’s lymphoma. Has the drug failed clinical trials? No. … Continue reading “This Common Cancer Treatment May Disappear”
